You are here

  • Home
  • Archive
  • Volume 61, Issue 5
  • Anti-inflammatory capacity of lactobacilli peptidoglycan: mucosal and systemic routes of administration promote similar effects - The Authors' reply

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Anti-inflammatory capacity of lactobacilli peptidoglycan: mucosal and systemic routes of administration promote similar effects - The Authors' reply
  1. Corinne Grangette,
  2. Elise Macho-Fernandez,
  3. Bruno Pot
  1. Lactic Acid Bacteria and Mucosal Immunity, Center for Infection and Immunity of Lille (CIIL), INSERM U1019-CNRS UMR 8204, Institut Pasteur de Lille (IPL), Lille, France
  1. Correspondence to Corinne Grangette, Center for Infection and Immunity of Lille (CIIL), Institut Pasteur de Lille (IPL), 1 rue du Pr Calmette, 59019 Lille, France; corinne.grangette{at}ibl.fr

https://doi.org/10.1136/gutjnl-2011-301194

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We thank Professor Matuchansky1 for his interest in our recent study.2 The strain specificity of the anti-inflammatory capacity of peptidoglycan (PGN) derived from probiotic lactobacilli was indeed shown using the 2,4,6-trinitrobenzene sulphonic acid colitis model and via the intraperitoneal route. We totally agree, however, that the relevant way of probiotic administration for clinical application is indeed the oral route. Related to this, it might be …

    View Full Text

    Footnotes

    • Funding Institut Pasteur of Lille, Association François Aupetit. Academic research support.

    • Competing interests None.

    • Provenance and peer review Not commissioned; internally peer reviewed.